시장보고서
상품코드
1322228

세계의 암 프로파일링 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2023-2031년)

Cancer Profiling Market (Product: Instruments and Consumables; and Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

발행일: | 리서치사: Transparency Market Research | 페이지 정보: 영문 195 Pages | 배송안내 : 2-10일 (영업일 기준)


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

암 프로파일링 시장-보고서 범위

세계의 암 프로파일링(Cancer Profiling) 시장에 대한 TMR 보고서는 과거 및 현재의 성장 동향, 2023년부터 2031년까지 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻을 수 있는 기회를 연구하고 있습니다. 2023년을 기준년도로, 2031년을 예측년도로 설정하여, 2017년부터 2031년까지 세계의 시장 매출 정보를 제공합니다. 또한 2023년부터 2031년까지 세계의 시장 CAGR(%)도 제공합니다.

보고서는 광범위한 조사를 거쳐 작성되었습니다. 1차 조사에서는 조사 활동의 대부분이 이루어졌으며 분석가들은 주요 오피니언 리더, 산업 리더, 오피니언 제조사와 인터뷰를 실시했습니다. 2차 조사에는 암 프로파일링 시장을 이해하기 위해 주요 기업의 제품 문헌, 연례 보고서, 보도 자료 및 관련 문서에 대한 참조가 포함됩니다.

세계의 암 프로파일링 시장 경쟁 상황을 자세히 파악하고 있습니다. 세계의 암 프로파일링 시장에서 활동하는 주요 플레이어가 확인되었으며, 이들 각각은 다양한 속성의 관점에서 프로파일링됩니다. 기업 개요, 재무 상황, 최근 동향, SWOT는 이 보고서에 소개 된 세계의 암 프로파일링 시장 플레이어 속성입니다.

목차

제1장 서문

제2장 전제 조건 및 연구 조사 방법

제3장 주요 요약 : 세계 시장

제4장 시장 개요

  • 소개
  • 개요
  • 시장 역학
  • 전 세계 시장 분석 및 예측(2017-2031년)

제5장 중요한 통찰

  • 규제 시나리오
  • 암 역학 : 지역별
  • 기술 진보
  • COVID-19 팬데믹의 산업에 대한 영향

제6장 시장 분석 및 예측 : 제품별

  • 소개 및 정의
  • 주요 발견/개발
  • 시장 금액 예측 : 제품별(2017-2031년)
    • 기기
      • 면역조직화학분석장치
      • In Situ 하이브리드화 장치
      • 중합효소 연쇄반응장치
      • DNA 시퀀서
      • 단편 분석기
    • 소모품
      • 시약과 키트
      • 기타
  • 시장 매력도 분석 : 제품별

제7장 시장 분석 및 예측 : 기술별

  • 소개 및 정의
  • 주요 발견/개발
  • 시장 금액 예측 : 기술별(2017-2031년)
    • 면역조직화학
    • 차세대 시퀀스
    • 중합효소 연쇄반응
    • In situ 하이브리드화
    • 마이크로어레이
    • 단편 분석
    • 기타
  • 시장 매력 분석 : 기술별

제8장 시장 분석 및 예측 : 암 유형별

  • 소개 및 정의
  • 주요 발견/개발
  • 시장 금액 예측 : 암 유형별(2017-2031년)
    • 유방암
    • 폐암
    • 결장직장암
    • 전립선암
    • 전립선암
    • 흑색종
    • 기타
  • 시장 매력도 분석 : 암 유형별

제9장 시장 분석 및 예측 : 최종 사용자별

  • 소개 및 정의
  • 주요 발견/개발
  • 시장 금액 예측 : 최종 사용자별(2017-2031년)
    • 병원
    • 진단 센터
    • 암 조사
    • 기타
  • 시장 매력도 분석 : 최종 사용자별

제10장 시장 분석 및 예측 : 지역별

  • 주요 조사 결과
  • 시장 금액 예측 : 지역별(2017-2031년)
    • 북미
    • 유럽
    • 아시아 태평양 지역
    • 남미
    • 중동 및 아프리카
  • 국가·지역별 시장 매력도

제11장 북미 시장 분석 및 예측

제12장 유럽 시장 분석 및 예측

제13장 아시아 태평양 시장 분석 및 예측

제14장 남미 시장 분석 및 예측

제15장 중동 및 아프리카 시장 분석 및 예측

제16장 경쟁 상황

  • 시장 기업-경쟁 매트릭스(기업의 계층 및 규모별)
  • 시장 점유율 분석 : 기업별(2022년)
  • 기업 개요
    • Abbott Laboratories
    • Agilent Technologies Inc.
    • F. Hoffmann-La Roche Ltd
    • HTG Molecular Diagnostics, Inc.
    • Illumina, Inc.
    • PerkinElmer Inc.
    • QIAGEN NV
    • Siemens Healthineers
    • Sysmex Corporation
    • Thermo Fisher Scientific Inc.
    • Hologic, Inc.
    • Guardant Health
LYJ 23.10.10

Cancer Profiling Market - Scope of Report

TMR's report on the global Cancer Profiling Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Cancer Profiling Market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Cancer Profiling Market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Cancer Profiling Market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Cancer Profiling Market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Cancer Profiling Market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Cancer Profiling Market.

The report delves into the competitive landscape of the global Cancer Profiling Market. Key players operating in the global Cancer Profiling Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Cancer Profiling Market profiled in this report.

Key Questions Answered in Global Cancer Profiling Market Report:

  • What is the sales/revenue generated by mobile photo printer across all regions during the forecast period?
  • What are the opportunities in the global Cancer Profiling Market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Cancer Profiling Market - Research Objectives and Research Approach

The comprehensive report on the global Cancer Profiling Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Cancer Profiling Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Cancer Profiling.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Cancer Profiling Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Cancer Profiling Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Regulatory Scenario for Cancer Profiling
  • 5.2. Cancer Epidemiology, by Region
  • 5.3. Technological Advancements in Cancer Profiling Technology
  • 5.4. COVID-19 Impact on the Industry

6. Global Cancer Profiling Market Analysis and Forecast, by Product

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Product, 2017-2031
    • 6.3.1. Instruments
      • 6.3.1.1. Immunohistochemistry Analyzers
      • 6.3.1.2. In Situ Hybridization Instruments
      • 6.3.1.3. Polymerase Chain Reaction Instruments
      • 6.3.1.4. DNA Sequencers
      • 6.3.1.5. Fragment Analyzers
    • 6.3.2. Consumables
      • 6.3.2.1. Reagents & Kits
      • 6.3.2.2. Others
  • 6.4. Market Attractiveness Analysis, by Product

7. Global Cancer Profiling Market Analysis and Forecast, by Technology

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Technology, 2017-2031
    • 7.3.1. Immunohistochemistry
    • 7.3.2. Next Generation Sequencing
    • 7.3.3. Polymerase Chain Reaction
    • 7.3.4. In Situ Hybridization
    • 7.3.5. Microarrays
    • 7.3.6. Fragment Analysis
    • 7.3.7. Others
  • 7.4. Market Attractiveness Analysis, by Technology

8. Global Cancer Profiling Market Analysis and Forecast, by Cancer Type

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Cancer Type, 2017-2031
    • 8.3.1. Breast Cancer
    • 8.3.2. Lung Cancer
    • 8.3.3. Colorectal Cancer
    • 8.3.4. Prostate Cancer
    • 8.3.5. Prostate Cancer
    • 8.3.6. Melanoma
    • 8.3.7. Others
  • 8.4. Market Attractiveness Analysis, by Cancer Type

9. Global Cancer Profiling Market Analysis and Forecast, by End-user

  • 9.1. Introduction & Definition
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by End-user, 2017-2031
    • 9.3.1. Hospitals
    • 9.3.2. Diagnostic Centers
    • 9.3.3. Cancer Research Institutes
    • 9.3.4. Others
  • 9.4. Market Attractiveness Analysis, by End-user

10. Global Cancer Profiling Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region, 2017-2031
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness By Country/Region

11. North America Cancer Profiling Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Product, 2017-2031
    • 11.2.1. Instruments
      • 11.2.1.1. Immunohistochemistry Analyzers
      • 11.2.1.2. In Situ Hybridization Instruments
      • 11.2.1.3. Polymerase Chain Reaction Instruments
      • 11.2.1.4. DNA Sequencers
      • 11.2.1.5. Fragment Analyzers
    • 11.2.2. Consumables
      • 11.2.2.1. Reagents & Kits
      • 11.2.2.2. Others
  • 11.3. Market Value Forecast, by Technology, 2017-2031
    • 11.3.1. Immunohistochemistry
    • 11.3.2. Next Generation Sequencing
    • 11.3.3. Polymerase Chain Reaction
    • 11.3.4. In Situ Hybridization
    • 11.3.5. Microarrays
    • 11.3.6. Fragment Analysis
    • 11.3.7. Others
  • 11.4. Market Value Forecast, by Cancer Type, 2017-2031
    • 11.4.1. Breast Cancer
    • 11.4.2. Lung Cancer
    • 11.4.3. Colorectal Cancer
    • 11.4.4. Prostate Cancer
    • 11.4.5. Prostate Cancer
    • 11.4.6. Melanoma
    • 11.4.7. Others
  • 11.5. Market Value Forecast, by End-user, 2017-2031
    • 11.5.1. Hospitals
    • 11.5.2. Diagnostic Centers
    • 11.5.3. Cancer Research Institutes
    • 11.5.4. Others
  • 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Product
    • 11.7.2. By Technology
    • 11.7.3. By Cancer Type
    • 11.7.4. By End-user
    • 11.7.5. By Country

12. Europe Cancer Profiling Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Product, 2017-2031
    • 12.2.1. Instruments
      • 12.2.1.1. Immunohistochemistry Analyzers
      • 12.2.1.2. In Situ Hybridization Instruments
      • 12.2.1.3. Polymerase Chain Reaction Instruments
      • 12.2.1.4. DNA Sequencers
      • 12.2.1.5. Fragment Analyzers
    • 12.2.2. Consumables
      • 12.2.2.1. Reagents & Kits
      • 12.2.2.2. Others
  • 12.3. Market Value Forecast, by Technology, 2017-2031
    • 12.3.1. Immunohistochemistry
    • 12.3.2. Next Generation Sequencing
    • 12.3.3. Polymerase Chain Reaction
    • 12.3.4. In Situ Hybridization
    • 12.3.5. Microarrays
    • 12.3.6. Fragment Analysis
    • 12.3.7. Others
  • 12.4. Market Value Forecast, by Cancer Type, 2017-2031
    • 12.4.1. Breast Cancer
    • 12.4.2. Lung Cancer
    • 12.4.3. Colorectal Cancer
    • 12.4.4. Prostate Cancer
    • 12.4.5. Prostate Cancer
    • 12.4.6. Melanoma
    • 12.4.7. Others
  • 12.5. Market Value Forecast, by End-user, 2017-2031
    • 12.5.1. Hospitals
    • 12.5.2. Diagnostic Centers
    • 12.5.3. Cancer Research Institutes
    • 12.5.4. Others
  • 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Italy
    • 12.6.5. Spain
    • 12.6.6. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Product
    • 12.7.2. By Technology
    • 12.7.3. By Cancer Type
    • 12.7.4. By End-user
    • 12.7.5. By Country/Sub-region

13. Asia Pacific Cancer Profiling Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Product, 2017-2031
    • 13.2.1. Instruments
      • 13.2.1.1. Immunohistochemistry Analyzers
      • 13.2.1.2. In Situ Hybridization Instruments
      • 13.2.1.3. Polymerase Chain Reaction Instruments
      • 13.2.1.4. DNA Sequencers
      • 13.2.1.5. Fragment Analyzers
    • 13.2.2. Consumables
      • 13.2.2.1. Reagents & Kits
      • 13.2.2.2. Others
  • 13.3. Market Value Forecast, by Technology, 2017-2031
    • 13.3.1. Immunohistochemistry
    • 13.3.2. Next Generation Sequencing
    • 13.3.3. Polymerase Chain Reaction
    • 13.3.4. In Situ Hybridization
    • 13.3.5. Microarrays
    • 13.3.6. Fragment Analysis
    • 13.3.7. Others
  • 13.4. Market Value Forecast, by Cancer Type, 2017-2031
    • 13.4.1. Breast Cancer
    • 13.4.2. Lung Cancer
    • 13.4.3. Colorectal Cancer
    • 13.4.4. Prostate Cancer
    • 13.4.5. Prostate Cancer
    • 13.4.6. Melanoma
    • 13.4.7. Others
  • 13.5. Market Value Forecast, by End-user, 2017-2031
    • 13.5.1. Hospitals
    • 13.5.2. Diagnostic Centers
    • 13.5.3. Cancer Research Institutes
    • 13.5.4. Others
  • 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.6.1. China
    • 13.6.2. Japan
    • 13.6.3. India
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Product
    • 13.7.2. By Technology
    • 13.7.3. By Cancer Type
    • 13.7.4. By End-user
    • 13.7.5. By Country/Sub-region

14. Latin America Cancer Profiling Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Product, 2017-2031
    • 14.2.1. Instruments
      • 14.2.1.1. Immunohistochemistry Analyzers
      • 14.2.1.2. In Situ Hybridization Instruments
      • 14.2.1.3. Polymerase Chain Reaction Instruments
      • 14.2.1.4. DNA Sequencers
      • 14.2.1.5. Fragment Analyzers
    • 14.2.2. Consumables
      • 14.2.2.1. Reagents & Kits
      • 14.2.2.2. Others
  • 14.3. Market Value Forecast, by Technology, 2017-2031
    • 14.3.1. Immunohistochemistry
    • 14.3.2. Next Generation Sequencing
    • 14.3.3. Polymerase Chain Reaction
    • 14.3.4. In Situ Hybridization
    • 14.3.5. Microarrays
    • 14.3.6. Fragment Analysis
    • 14.3.7. Others
  • 14.4. Market Value Forecast, by Cancer Type, 2017-2031
    • 14.4.1. Breast Cancer
    • 14.4.2. Lung Cancer
    • 14.4.3. Colorectal Cancer
    • 14.4.4. Prostate Cancer
    • 14.4.5. Prostate Cancer
    • 14.4.6. Melanoma
    • 14.4.7. Others
  • 14.5. Market Value Forecast, by End-user, 2017-2031
    • 14.5.1. Hospitals
    • 14.5.2. Diagnostic Centers
    • 14.5.3. Cancer Research Institutes
    • 14.5.4. Others
  • 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Product
    • 14.7.2. By Technology
    • 14.7.3. By Cancer Type
    • 14.7.4. By End-user
    • 14.7.5. By Country/Sub-region

15. Middle East & Africa Cancer Profiling Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Product, 2017-2031
    • 15.2.1. Instruments
      • 15.2.1.1. Immunohistochemistry Analyzers
      • 15.2.1.2. In Situ Hybridization Instruments
      • 15.2.1.3. Polymerase Chain Reaction Instruments
      • 15.2.1.4. DNA Sequencers
      • 15.2.1.5. Fragment Analyzers
    • 15.2.2. Consumables
      • 15.2.2.1. Reagents & Kits
      • 15.2.2.2. Others
  • 15.3. Market Value Forecast, by Technology, 2017-2031
    • 15.3.1. Immunohistochemistry
    • 15.3.2. Next Generation Sequencing
    • 15.3.3. Polymerase Chain Reaction
    • 15.3.4. In Situ Hybridization
    • 15.3.5. Microarrays
    • 15.3.6. Fragment Analysis
    • 15.3.7. Others
  • 15.4. Market Value Forecast, by Cancer Type, 2017-2031
    • 15.4.1. Breast Cancer
    • 15.4.2. Lung Cancer
    • 15.4.3. Colorectal Cancer
    • 15.4.4. Prostate Cancer
    • 15.4.5. Prostate Cancer
    • 15.4.6. Melanoma
    • 15.4.7. Others
  • 15.5. Market Value Forecast, by End-user, 2017-2031
    • 15.5.1. Hospitals
    • 15.5.2. Diagnostic Centers
    • 15.5.3. Cancer Research Institutes
    • 15.5.4. Others
  • 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Product
    • 15.7.2. By Technology
    • 15.7.3. By Cancer Type
    • 15.7.4. By End-user
    • 15.7.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 16.2. Market Share Analysis, by Company (2022)
  • 16.3. Company Profiles
    • 16.3.1. Abbott Laboratories
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. Agilent Technologies Inc.
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. F. Hoffmann-La Roche Ltd
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. HTG Molecular Diagnostics, Inc.
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. Illumina, Inc.
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. PerkinElmer Inc.
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. QIAGEN N.V.
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Siemens Healthineers
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview
    • 16.3.9. Sysmex Corporation
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. SWOT Analysis
      • 16.3.9.5. Strategic Overview
    • 16.3.10. Thermo Fisher Scientific Inc.
      • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.10.2. Product Portfolio
      • 16.3.10.3. Financial Overview
      • 16.3.10.4. SWOT Analysis
      • 16.3.10.5. Strategic Overview
    • 16.3.11. Hologic, Inc.
      • 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.11.2. Product Portfolio
      • 16.3.11.3. Financial Overview
      • 16.3.11.4. SWOT Analysis
      • 16.3.11.5. Strategic Overview
    • 16.3.12. Guardant Health
      • 16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.12.2. Product Portfolio
      • 16.3.12.3. Financial Overview
      • 16.3.12.4. SWOT Analysis
      • 16.3.12.5. Strategic Overview
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제